These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8086668)

  • 41. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
    Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
    Lamond JP; Wang M; Kinsella TJ; Boothman DA
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):369-76. PubMed ID: 8892462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11).
    Digkas E; Kareli D; Chrisafi S; Passadaki T; Mantadakis E; Hatzimichail A; Vargemezis V; Lialiaris T
    Food Chem Toxicol; 2010 Jan; 48(1):242-9. PubMed ID: 19819285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
    Boscia RE; Korbut T; Holden SA; Ara G; Teicher BA
    Int J Cancer; 1993 Jan; 53(1):118-23. PubMed ID: 8416195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
    Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
    Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of adriamycin cytotoxicity and transport in drug-sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A.
    Larrivée B; Averill DA
    Cancer Chemother Pharmacol; 2000; 45(3):219-30. PubMed ID: 10663640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
    Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
    Dalezis P; Geromichalos GD; Voyatzi S; Trafalis D; Athanassiou AE; Koutsilieris M; Papageorgiou A
    J BUON; 2006; 11(3):323-7. PubMed ID: 17309157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
    Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
    Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced albumin binding promotes the stability and activity of topotecan in human blood.
    Mi Z; Malak H; Burke TG
    Biochemistry; 1995 Oct; 34(42):13722-8. PubMed ID: 7577964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
    Gradzka I; Szumiel I
    Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
    Nakatsu S; Kondo S; Kondo Y; Yin D; Peterson JW; Kaakaji R; Morimura T; Kikuchi H; Takeuchi J; Barnett GH
    Cancer Chemother Pharmacol; 1997; 39(5):417-23. PubMed ID: 9054955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
    Grabowski D; Ganapathi R
    Ann N Y Acad Sci; 1996 Dec; 803():306-7. PubMed ID: 8993524
    [No Abstract]   [Full Text] [Related]  

  • 56. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.
    Yoshida A; Ueda T; Wano Y; Nakamura T
    Jpn J Cancer Res; 1993 May; 84(5):566-73. PubMed ID: 8391526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
    Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
    Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
    Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
    Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
    Sugimori M; Ejima A; Ohsuki S; Uoto K; Mitsui I; Matsumoto K; Kawato Y; Yasuoka M; Sato K; Tagawa H
    J Med Chem; 1994 Sep; 37(19):3033-9. PubMed ID: 7932525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
    Lamond JP; Wang M; Kinsella TJ; Boothman DA
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.